Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >

The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan ↗

March 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In...

Via Benzinga

The Ruble Is Rubble ↗

March 03, 2022

MSCI says Russian companies are

Via Talk Markets

Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting ↗

February 25, 2022

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically...

Via Benzinga

Dampening Exuberance ↗

February 09, 2022

The bond sell-off halted today but the Fed's plans mean this will resume.

Via Talk Markets

Weakened Tech Stocks ↗

February 03, 2022

There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.

Via Talk Markets

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply ↗

January 12, 2022

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...

Via Benzinga

Christmas is Coming ↗

December 23, 2021

November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month.

Via Talk Markets

A Bit Of Good News ↗

December 22, 2021

US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%.

Via Talk Markets

Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026 ↗

December 16, 2021

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s...

Via Benzinga

Uncertain Times ↗

December 15, 2021

The UK inflation rate last month was 5.1%, not a good omen.

Via Talk Markets

Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma ↗

November 29, 2021

The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for...

Via Benzinga

Why Are Biogen Shares Gaining Today? ↗

November 12, 2021

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:...

Via Benzinga

Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial ↗

November 11, 2021

Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...

Via Benzinga

The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts ↗

November 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...

Via Benzinga

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

Multiple Bits Of Bad News ↗

September 28, 2021

Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.

Via Talk Markets

Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug ↗

September 28, 2021

Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab...

Via Benzinga

A Day Of Huge Market Moves ↗

September 21, 2021

It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority.

Via Talk Markets

Pressure Day ↗

September 13, 2021

Today a recovery came to markets with a particular impact on uranium shares.

Via Talk Markets

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

A Weak Week ↗

September 10, 2021

Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.

Via Talk Markets

Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential ↗

September 10, 2021

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)

Via Benzinga

Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma ↗

September 07, 2021

Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-...

Via Benzinga

Mu - The Newest Worry ↗

September 03, 2021

Today London and New York fell on the huge drop in new employment levels in August.

Via Talk Markets

Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free ↗

August 30, 2021

Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ...

Via Benzinga

The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week ↗

August 29, 2021

Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and...

Via Talk Markets

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week ↗

August 29, 2021

Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.